Effect of Tropomyosin-1 on RCC Radiosensitivity and Its Regulatory Mechanism

Background Radiotherapy is the main therapeutic approach for patients suffering from advanced renal cell carcinoma (RCC). Given the critical role that radiotherapy plays in the treatment of this condition, it is vital to improve the radiosensitivity of RCC to enhance treatment efficacy. One protein of particular interest in this context is tropomyosin-1 (TPM1), which is a cytoskeletal protein linked to actin. Research has demonstrated that TPM1 expression is often reduced in several malignant tumors, including RCC. Despite these findings, the relationship between TPM1 and RCC radiosensitivity has not yet been fully explored. Methods A comprehensive biological assessment of TPM1 expression was performed in the present study. Its potential prognostic implications were explored by utilizing the Gene Expression Profiling Interactive Analysis (GEPIA) database, which allowed an analysis of large-scale expression data and to derive meaningful conclusions regarding the role of TPM1 in RCC. An evaluation of immunohistochemical staining in tissue samples obtained from 10 patients diagnosed with RCC was also conducted. This dual approach enabled us to corroborate the study findings with experimental data, thus enhancing the validity of the assessment. Moreover, specific mechanisms through which TPM1 exerted its influence on RCC radiosensitivity were explored. Results A comprehensive analysis indicated that TPM1 expression was markedly decreased in RCC. This down-regulation was associated with a more favorable patient prognosis. Furthermore, TPM1 integration with radiation therapy was effective in inhibiting the proliferation of RCC cells. This combination promoted apoptosis and led to significant alterations in cell cycle progression. Additionally, it enhanced DNA damage while simultaneously reducing the cells' ability to repair it. Notably, a substantial reduction in the invasive capacities of these cancer cells was observed when TPM1 was combined with radiation therapy. As a result, the investigation clarified the underlying mechanisms through which TPM1 influenced RCC radiosensitivity. This modulation occurred primarily through regulation of the Wnt/β-catenin signaling pathway. Thereby, TPM1 appeared to play a pivotal role in enhancing the effectiveness of renal cancer radiation treatment, ultimately contributing to improved therapeutic outcomes. Conclusion The present research study underscored the importance of TPM1 in determining the radiosensitivity of RCC. The findings suggested that enhancing TPM1 expression levels may be a viable and promising approach to improve the overall effectiveness of radiotherapy in treating this type of cancer. By focusing on the modulation of TPM1 expression, there may be a potential to increase the responsiveness of RCC to radiation treatment and improve patient outcomes in clinical settings.